Message #27 From:
NewsBot Date: November 22, 2006 04:00:00 AM
SVNT News Savient Pharmaceuticals to Present at Lazard Capital Markets Third Annual Life Sciences Conference
EAST BRUNSWICK, N.J.--(BUSINESS WIRE)--Savient Pharmaceuticals, Inc. (NASDAQ:SVNT), a biopharmaceutical company
focused on developing, manufacturing and marketing novel therapeutic
products for unmet medical needs, today announced that Christopher
Clement, President and Chief Executive Officer of Savient
Pharmaceuticals, will present a corporate update at the upcoming Lazard
Capital Markets Third Annual Life Sciences Conference. The presentation
is scheduled for 8:30 AM (Eastern Time) on Wednesday, November 29, 2006.
The event will be held from November 28 - 29, 2006 at the New York
Palace Hotel in New York City.
Individuals may listen to a live web cast of the presentation by logging
on to the Investor Relations section of Savient Pharmaceuticals’
web site, www.savientpharma.com
a few minutes prior to start time to download any necessary software.
About Savient Pharmaceuticals, Inc.
Savient Pharmaceuticals is a biopharmaceutical company engaged in
developing, manufacturing and marketing pharmaceutical products that
target unmet medical needs in both niche and broader markets. The
Company's lead product development candidate, Puricase®
(PEG-uricase) for treatment failure gout, has reported positive Phase 1
and 2 clinical data; Phase 3 clinical studies began in May 2006.
Savient's experienced management team is committed to advancing its
pipeline and expanding its product portfolio by in-licensing late-stage
compounds and exploring co-promotion and co-development opportunities
that fit the Company's expertise in biopharmaceuticals with an initial
focus in rheumatology. Savient also markets Oxandrin®
(oxandrolone tablets, USP) CIII in the U.S. Puricase is a registered
trademark of Mountain View Pharmaceuticals, Inc. Further information on
Savient can be accessed by visiting: www.savientpharma.com.
